Last updated: September 9, 2026
DIGIBIND, an ovine digoxin immune Fab product, is a legacy biologic antidote for life-threatening digoxin toxicity. Its U.S. commercial status is inactive: the product was discontinued, leaving DigiFab and other digoxin immune Fab supply as the relevant competitive alternatives. DIGIBIND has no meaningful current revenue trajectory disclosed by its former commercial sponsor, and its commercial value is tied primarily to historical hospital demand, replacement supply, and manufacturing know-how rather than active patent exclusivity.
What is DIGIBIND and how does it work?
DIGIBIND is an intravenous preparation of digoxin immune Fab fragments derived from sheep immunized with digoxin derivatives. The antibody fragments bind free digoxin and related cardiac glycosides in the bloodstream. The resulting complexes are cleared through the kidneys, reducing digoxin’s pharmacologic effects.
The product was developed for severe or potentially fatal digoxin toxicity, including:
- Ventricular arrhythmias
- Bradyarrhythmias and heart block
- Hyperkalemia associated with acute digoxin poisoning
- Significant toxicity after accidental or intentional ingestion
- Toxicity from related cardiac glycosides such as digitoxin, although clinical use depends on the specific exposure
DIGIBIND received U.S. regulatory approval as a biologic product. Its historical label identified GlaxoSmithKline as the manufacturer and sponsor. The product is administered in vials containing digoxin immune Fab powder for reconstitution.[1]
What is the FDA status of DIGIBIND?
DIGIBIND is not an active U.S. commercial product. FDA product records and labeling identify it as discontinued. Its historical application and labeling remain relevant for clinical and regulatory reference, but discontinuation removes current commercial sales from the U.S. market.[2]
| Regulatory item |
DIGIBIND status |
| Active ingredient |
Digoxin immune Fab |
| Product type |
Ovine antibody Fab biologic |
| Historical indication |
Life-threatening or potentially life-threatening digoxin toxicity |
| U.S. sponsor/manufacturer |
GlaxoSmithKline, historically |
| FDA status |
Discontinued |
| Current U.S. commercial position |
No active DIGIBIND sales |
| Main replacement product |
DigiFab and other digoxin immune Fab supply |
| Orange Book status |
Not the principal regulatory record for this biologic |
DIGIBIND’s regulatory history differs from that of a conventional small-molecule drug. Biologic products are generally tracked through Biologics License Application records and FDA labeling rather than relying exclusively on the Orange Book framework used for small-molecule products. The relevant market-entry barriers are therefore manufacturing consistency, regulatory approval, clinical supply reliability, and institutional procurement rather than a conventional generic substitution pathway.
When did DIGIBIND lose exclusivity?
DIGIBIND’s commercial protection is no longer best analyzed through a live patent-exclusivity date. The product is a mature biologic with an inactive U.S. commercial status. Any original patents associated with the antibody technology, production process, or formulation would generally have expired or become commercially immaterial after decades of development and marketing.
No current, commercially significant DIGIBIND patent estate is identified as controlling U.S. market entry. The primary competitive barriers are:
- Regulatory approval for the biologic product.
- Access to immunized ovine source material.
- Control of purification and fragmentation processes.
- Product comparability and release testing.
- Hospital stocking and emergency-distribution infrastructure.
The absence of an active patent moat does not make market entry simple. Digoxin immune Fab is a specialized antidote with limited demand, complex manufacturing, and high consequences for supply interruption.
How large is the DIGIBIND market?
The market is small in patient volume but strategically important to hospitals. Digoxin toxicity is infrequent relative to common cardiovascular conditions, yet treatment demand is urgent because the product is used in emergency settings where delayed availability can increase clinical risk.
Market economics have several defining characteristics:
- Demand is episodic rather than chronic.
- Hospitals and poison centers influence purchasing decisions.
- Emergency departments and intensive-care units require rapid access.
- Purchases are often driven by preparedness rather than routine utilization.
- Product volume is low, but vial prices can be substantial.
- Stocking levels are affected by local prescribing patterns, renal disease prevalence, elderly populations, and poison-center activity.
- Shortages can shift demand rapidly to the remaining supplier.
The market is therefore closer to an emergency biologic market than to a conventional branded pharmaceutical market. Revenue depends on unit price, hospital inventory policies, and supply continuity rather than on large prescription volumes.
What was the financial trajectory of DIGIBIND?
No standalone DIGIBIND revenue series is publicly reported by the former sponsor. GlaxoSmithKline’s public financial reporting did not break out DIGIBIND as a separate operating segment or product line. As a result, precise historical revenue, gross margin, and operating-profit figures cannot be reliably assigned to DIGIBIND.
The commercial trajectory can nevertheless be described in four phases.
Launch and specialist-antidote adoption
DIGIBIND entered a niche market created by the need for a targeted reversal agent for severe digoxin toxicity. Early adoption was supported by the product’s clinical utility and the lack of an equivalent antibody-based antidote.
Mature branded biologic phase
The product became part of hospital toxicology and cardiology protocols. Demand remained limited in volume but relatively resilient because acute digoxin toxicity requires immediate treatment and has few alternatives.
Competitive replacement phase
DigiFab entered the U.S. market as another digoxin immune Fab product. The presence of an alternative reduced the strategic value of a single-brand franchise and gave hospitals a substitute when DIGIBIND supply was constrained.[3]
Discontinuation phase
After DIGIBIND’s discontinuation, demand migrated to alternative digoxin immune Fab products. The value of the DIGIBIND brand declined to zero as an active U.S. revenue source, while the underlying product category retained clinical relevance.
What companies compete with DIGIBIND?
The principal U.S. commercial alternative has been DigiFab, a digoxin immune Fab product associated with BTG and subsequently with SERB following SERB’s acquisition of BTG’s pharmaceutical business.[4]
| Product |
Active ingredient |
Commercial position |
| DIGIBIND |
Digoxin immune Fab |
Historical product; discontinued in the U.S. |
| DigiFab |
Digoxin immune Fab |
Principal U.S. replacement and category competitor |
| Other regional products |
Digoxin immune Fab or comparable antidote products |
Availability varies by country and regulatory jurisdiction |
DigiFab competes on regulatory availability, hospital contracts, inventory reliability, physician familiarity, and emergency distribution. Because the products treat a time-sensitive condition, supply reliability may carry more weight than conventional brand differentiation.
What patents protect DIGIBIND?
No active, material patent portfolio is publicly associated with DIGIBIND as a current commercial product. Historical protection likely covered elements such as:
- Antibody generation against digoxin
- Ovine immunization methods
- Fab fragmentation and purification
- Stabilized injectable formulations
- Manufacturing and quality-control processes
Those protections are distinct from current regulatory exclusivity. The original product entered the market decades ago, making expiration of foundational patent rights expected. The remaining defensibility lies in trade secrets, process validation, analytical methods, supplier relationships, and regulatory knowledge.
Are formulation patents important for digoxin immune Fab?
Formulation patents may protect excipient composition, stability, lyophilization, reconstitution characteristics, or storage conditions. Their practical value is limited if the patent term has expired or if a competitor can design around the claims while producing an equivalent emergency antidote.
For a product such as DIGIBIND, manufacturing patents are potentially more important than dosage-form patents because the product is a complex antibody fragment rather than a simple tablet or injectable small molecule.
Is DIGIBIND subject to Paragraph IV challenges?
A conventional Paragraph IV challenge is not the central pathway for DIGIBIND. Paragraph IV litigation applies primarily to Abbreviated New Drug Applications for small-molecule products listed in the Orange Book. Digoxin immune Fab is a biologic, and follow-on competition generally proceeds through biologic regulatory pathways rather than a standard ANDA Paragraph IV process.
The practical equivalent of market-entry competition would involve:
- A full biologics license application
- A biosimilar or interchangeable biosimilar pathway, if applicable
- Product-specific FDA requirements for analytical and clinical comparability
- Patent litigation under biologic patent-dispute procedures, where relevant
- Independent regulatory approval without reliance on a conventional Orange Book listing
No major active Paragraph IV litigation is identified as affecting DIGIBIND.
Is there biosimilar risk for DIGIBIND?
Biosimilar risk is theoretically possible but commercially limited. Digoxin immune Fab is a complex, polyclonal-derived antibody fragment product. Demonstrating sufficient analytical, functional, manufacturing, and clinical similarity may be more difficult than for a simpler recombinant monoclonal antibody.
The main constraints on biosimilar development are:
- Small addressable market
- Low and irregular annual treatment volume
- Expensive biologic manufacturing
- Need for specialized immunization and purification systems
- Emergency-use procurement requirements
- Limited opportunity to build a large outpatient franchise
- Potentially difficult return on development investment
A follow-on product could still enter if the incumbent price is high, supply is unreliable, or government and hospital buyers create sufficient volume. The market is more likely to attract a specialized antidote manufacturer than a large-scale biosimilar developer.
What litigation and settlement agreements affect DIGIBIND?
No prominent current patent litigation or settlement agreement is identified as governing DIGIBIND’s U.S. market. The product’s main legal issue is commercial discontinuation rather than an ongoing patent dispute.
Any historical disputes involving digoxin immune Fab products would need to be evaluated separately by product, sponsor, patent family, and jurisdiction. DIGIBIND’s inactive status reduces the likelihood that legacy litigation would materially affect current market access.
What are the manufacturing and intellectual-property barriers?
Manufacturing is the strongest remaining barrier to entry.
Ovine antibody production
The product depends on controlled ovine immunization and collection of antibody-containing plasma. This creates biological-source, animal-health, and supply-chain requirements that do not apply to ordinary chemical drugs.
Fab generation and purification
The manufacturing process must generate Fab fragments with appropriate binding activity and remove unwanted immunoglobulin components, aggregates, contaminants, and process impurities.
Potency and release testing
Each batch requires validated assays for antibody binding, concentration, sterility, purity, stability, and product consistency. Emergency antidotes require a high level of reliability because hospitals cannot easily substitute another therapy once a toxic exposure occurs.
Regulatory comparability
A new sponsor must establish consistency across manufacturing changes and demonstrate that the product has the required pharmacologic activity. This raises development costs even when the active ingredient is no longer patent protected.
How does DIGIBIND compare with DigiFab?
| Factor |
DIGIBIND |
DigiFab |
| U.S. status |
Discontinued |
Active replacement category product |
| Product type |
Ovine digoxin immune Fab |
Ovine digoxin immune Fab |
| Clinical role |
Historical treatment for severe digoxin toxicity |
Current replacement treatment |
| Patent value |
No material current estate identified |
Protection depends on current manufacturing, formulation, and regulatory rights |
| Revenue outlook |
No current U.S. product revenue |
Retains category revenue opportunity |
| Main risk |
Product discontinuation |
Supply reliability, pricing, and follow-on competition |
| Market access |
Historical hospital adoption |
Hospital contracts and emergency-stock positioning |
The products are clinically similar in purpose, but commercial substitution depends on FDA availability, physician protocols, hospital formularies, and inventory. A discontinued product cannot capture new U.S. sales even if its clinical profile remains familiar.
What generic launch risks exist?
The risk of a conventional generic launch is low because DIGIBIND is a biologic rather than a standard small-molecule product. The more relevant risk is entry by another digoxin immune Fab manufacturer.
Potential entry scenarios include:
Single incumbent with stable supply
DigiFab or another incumbent maintains reliable production. Pricing remains supported by emergency demand and limited competition.
Follow-on biologic entry
A new sponsor obtains approval for a comparable digoxin immune Fab product. Hospital buyers gain negotiating leverage, but the entrant must overcome limited market volume and manufacturing complexity.
Supply disruption
A manufacturing interruption causes hospitals and distributors to seek substitute supply. In this scenario, the key commercial asset is inventory and distribution capacity rather than patent ownership.
International fragmentation
Different products may be available in the United States, Europe, Canada, and other markets. Regulatory approval and supply conditions must be assessed jurisdiction by jurisdiction.
What is the geographic coverage of DIGIBIND?
DIGIBIND’s historical regulatory and commercial significance was strongest in the United States. Current geographic availability is product-specific. The discontinuation of DIGIBIND in the U.S. does not establish that every international market has identical status.
For diligence purposes, geographic analysis should separate:
- U.S. FDA approval and discontinuation
- European regulatory authorization
- Canadian and Australian availability
- Hospital procurement in emerging markets
- Importation and compassionate-use mechanisms
- Local antidote-stockpiling policies
There is no basis to treat DIGIBIND as a globally active brand after its U.S. discontinuation.
What is the investment outlook for the digoxin immune Fab market?
The category is commercially defensive but not a high-growth pharmaceutical market. Its strengths are clinical necessity, limited substitution during emergencies, and relatively high switching friction at the hospital level. Its weaknesses are low patient volume, difficult manufacturing, limited patent protection, and uncertain revenue concentration.
| Investment factor |
Assessment |
| Market growth |
Low to modest |
| Volume predictability |
Low; demand is episodic |
| Pricing power |
Potentially meaningful, constrained by hospital budgets and public scrutiny |
| Patent protection |
Weak for legacy DIGIBIND |
| Manufacturing barrier |
High |
| Generic substitution |
Low through conventional generic pathways |
| Biosimilar threat |
Low to moderate, depending on economics |
| Supply-chain risk |
High |
| Revenue concentration |
High in the active supplier |
| Strategic value |
Higher for an antidote-focused portfolio than for a broad primary-care portfolio |
The financial opportunity is concentrated in the active replacement product and in supply reliability. DIGIBIND itself has no current U.S. growth trajectory because the product has been discontinued.
Key Takeaways
- DIGIBIND is a discontinued U.S. digoxin immune Fab biologic.
- Its historical sponsor was GlaxoSmithKline.
- DigiFab is the principal U.S. replacement product and category competitor.
- DIGIBIND has no identified active patent estate with material current commercial value.
- Paragraph IV litigation is not the relevant competitive framework because the product is a biologic.
- Biosimilar entry is possible but constrained by low market volume and complex ovine-antibody manufacturing.
- No standalone DIGIBIND revenue series is publicly disclosed.
- The market is small, emergency-driven, and supply-sensitive.
- Current commercial value resides in active replacement products, manufacturing capability, regulatory approvals, and hospital distribution.
- The most significant business risk is supply interruption, not ordinary generic substitution.
FAQs
Is DIGIBIND still available in the United States?
No. DIGIBIND is listed as discontinued in U.S. regulatory and labeling records. DigiFab and other available digoxin immune Fab products are the relevant alternatives.
Is DIGIBIND the same as DigiFab?
Both are digoxin immune Fab products derived from ovine antibodies and used for severe digoxin toxicity. They are separate branded products and should not be treated as the same commercial product.
Does DIGIBIND have an Orange Book patent listing?
The Orange Book is not the primary regulatory framework for this biologic. DIGIBIND’s relevant records are associated with its biologic license and FDA labeling, and no material current patent position is identified.
Can a new manufacturer launch a digoxin immune Fab product?
Yes, but the manufacturer would need to satisfy FDA biologic requirements and establish reliable ovine immunization, Fab production, purification, potency, sterility, and quality-control systems.
Why is digoxin immune Fab commercially valuable despite low demand?
Hospitals need immediate access to the antidote for rare but potentially fatal poisoning events. Emergency necessity supports stocking demand even when annual treatment volume is limited.
References
- U.S. Food and Drug Administration. (n.d.). DIGIBIND (digoxin immune Fab) prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: DIGIBIND application and product records. FDA.
- U.S. Food and Drug Administration. (n.d.). DigiFab (digoxin immune Fab) prescribing information. FDA.
- SERB Pharmaceuticals. (2019). SERB acquisition of BTG’s pharmaceutical business. SERB Pharmaceuticals.
